Daiichi Sankyo Co Ltd (4568.T)
Latest Key Developments (Source: Significant Developments)
April 27 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>::Daiichi Sankyo - making initial 15 billion yen investment to optimize and enhance manufacturing capabilities to support growing antibody drug conjugate pipeline. Full Article
April 18 (Reuters) - GlaxoSmithKline Plc
April 17 (Reuters) - Htg Molecular Diagnostics Inc
Sosei Group unit signs alliance for R & D of new small molecule therapeutic drug with DAIICHI SANKYO COMPANY LIMITED.
Sosei Group Corp <4565.T>:Says its subsidiary Heptares signed an alliance for R & D of new small molecule therapeutic drug with DAIICHI SANKYO COMPANY LIMITED. on March 13. Full Article
Amring Pharmaceuticals Inc : Amring pharmaceuticals inc - acquired six andas from luitpold pharmaceuticals inc and alphaforce l.l.p. .Amring pharmaceuticals inc - acquired andas include niche otic and ophthalmic pharmaceuticals. Full Article
EU Medicines Agency: EU medicines Agency recommendations for February 2017 . EU Medicines Agency recommends approval Of Daiichi Sankyo's anticoagulant Edoxaban . EU Medicines Agency says adopted positive opinion recommending changes to the terms of the marketing authorisation for the medicinal product Darzalex . EU Medicines Agency recommends approval of Hospira UK Limited's Pemetrexed for treatment of non-small cell lung cancer Source (http://bit.ly/2lCHPks) Further company coverage: [4568.T] ((Bangalore.email@example.com;)). Full Article
Charleston Laboratories : Charleston laboratories, inc. And daiichi sankyo, inc. Receive complete response letter from fda for new drug application for cl-108 (hydrocodone, acetaminophen, promethazine) tablets for oral use .Charleston laboratories - crl stated nda in its present form was not approved and provided guidance on information needed to resolve matters identified. Full Article
Kite Pharma Inc
Daiichi Sankyo Co Ltd <4568.T> : Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA" -R&I .Rating outlook negative -R&I. Full Article
TOKYO Japanese drugmaker Daiichi Sankyo denied on Thursday it received a takeover bid last year from Britain's AstraZeneca, following speculation that sent its share price soaring as much as 13 percent and triggered a trade suspension.